See more : Bank of America Corporation (BAC-PB) Income Statement Analysis – Financial Results
Complete financial analysis of Equillium, Inc. (EQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Equillium, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Natural Resource Partners L.P. (NRP) Income Statement Analysis – Financial Results
- Terranueva Corporation (TEQ.CN) Income Statement Analysis – Financial Results
- Plaza Centers N.V. (PLAZ.L) Income Statement Analysis – Financial Results
- YungShin Global Holding Corporation (3705.TW) Income Statement Analysis – Financial Results
- Swicorp Wabel Reit Fund (4345.SR) Income Statement Analysis – Financial Results
Equillium, Inc. (EQ)
About Equillium, Inc.
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 36.08M | 15.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 126.00K | 118.00K | 72.00K | 45.00K | 23.00K | 6.10K | 122.00 |
| Gross Profit | 35.96M | 15.64M | -72.00K | -45.00K | -23.00K | -6.10K | -122.00 |
| Gross Profit Ratio | 99.65% | 99.25% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 37.04M | 37.55M | 26.38M | 19.38M | 17.64M | 4.94M | 1.33M |
| General & Administrative | 13.57M | 17.24M | 11.41M | 10.16M | 9.09M | 3.67M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.57M | 17.24M | 11.41M | 10.16M | 9.09M | 3.67M | 378.21K |
| Other Expenses | 0.00 | -352.00K | -1.27M | -265.00K | 1.13M | -4.64M | 0.00 |
| Operating Expenses | 50.61M | 54.79M | 37.79M | 29.55M | 26.73M | 8.62M | 1.71M |
| Cost & Expenses | 50.61M | 54.79M | 37.79M | 29.55M | 26.73M | 8.62M | 1.71M |
| Interest Income | 2.33M | 420.00K | 57.00K | 476.00K | 1.39M | 339.62K | 0.00 |
| Interest Expense | 491.00K | 1.05M | 1.07M | 1.10M | 279.00K | 2.56M | 379.39K |
| Depreciation & Amortization | 126.00K | 118.00K | 72.00K | 45.00K | 23.00K | 6.10K | 122.00 |
| EBITDA | -12.14M | -61.26M | -37.91M | -28.67M | -25.30M | -10.69M | -1.88M |
| EBITDA Ratio | -33.64% | -101.39% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -14.52M | -62.08M | -37.79M | -29.55M | -26.73M | -8.62M | -1.71M |
| Operating Income Ratio | -40.24% | -393.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.77M | -352.00K | -1.27M | -265.00K | 1.13M | -4.64M | -549.82K |
| Income Before Tax | -12.76M | -62.43M | -39.05M | -29.81M | -25.60M | -13.25M | -2.26M |
| Income Before Tax Ratio | -35.35% | -396.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 580.00K | 45.28M | -72.00K | -45.00K | -23.00K | 140.51K | -2.00 |
| Net Income | -13.34M | -107.71M | -38.98M | -29.77M | -25.58M | -13.25M | -2.26M |
| Net Income Ratio | -36.96% | -683.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.38 | -3.19 | -1.35 | -1.46 | -1.47 | -1.09 | -0.13 |
| EPS Diluted | -0.38 | -3.19 | -1.35 | -1.46 | -1.47 | -1.09 | -0.13 |
| Weighted Avg Shares Out | 34.73M | 33.73M | 28.81M | 20.36M | 17.38M | 12.19M | 17.45M |
| Weighted Avg Shares Out (Dil) | 34.73M | 33.73M | 28.81M | 20.36M | 17.38M | 12.19M | 17.45M |
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the third quarter 2024 and provided...
Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth
Equillium (EQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Equillium, Inc. (EQ) Beats Q2 Earnings and Revenue Estimates
Equillium, Inc. (EQ) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.15 per share. This compares to loss of $0.10 per share a year ago.
Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced second quarter 2024 estimated ending cash, cash equivalents and short-term investments of approximately...
Equillium to be included in the Russell Microcap® Index
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the...
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that on May 31, 2024, the Compensation Committee of Equillium's Board of Directors granted...
Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced positive topline data from its Phase 2, single dose,...
Equillium to Present at the Jefferies Global Healthcare Conference
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the Jefferies Global Healthcare Conference taking place at the...
Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it has surpassed the interim enrollment target for the Phase 3 EQUATOR study...
Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates
Equillium, Inc. (EQ) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.11 per share a year ago.
Source: https://incomestatements.info
Category: Stock Reports